Efficacy Safety Study Comparing 2 Doses of NVP After Initiating Rifampin-containing TB Therapy
A 48 Week, Randomized, Open-label, 2 Arm Study to Compare the Efficacy, Safety and Tolerability of HAART Containing Nevirapine 400mg/Day Versus Nevirapine 600 mg/Day in HIV-1 Infected Patients Started at 2-6 Weeks After Initiating Rifampin Containing Antituberculous Therapy
Sponsor: Bamrasnaradura Infectious Diseases Institute
This PHASE2 trial investigates HIV Infections and Tuberculosis and is currently completed. Bamrasnaradura Infectious Diseases Institute leads this study, which shows 6 recorded versions since 2005 — indicating limited longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE2
-
Aug 2020 — Jan 2021 [monthly]
Completed PHASE2
-
Jun 2018 — Aug 2020 [monthly]
Completed PHASE2
▶ Show 1 earlier version
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE2
First recorded
Oct 2005
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Bamrasnaradura Infectious Diseases Institute
- Central General Chest Institute
- Chiang Rai Hospital
- King Chulalongkorn Memorial Hospital
- Labor and Welfare
- Thai GPO
- Thai MOPH
- The HIV Netherlands Australia Thailand Research Collaboration
- The Research Institute of Tuberculosis (Japan)
- other sponsors:Japanese MOPH
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
- • Bangkok, Thailand
- • Chiang Rai, Thailand
- • Nonthaburi, Thailand